The use of neutrophil elastase inhibitor in the treatment of acute lung injury after pneumonectomy

J Cardiothorac Surg. 2013 Apr 8:8:69. doi: 10.1186/1749-8090-8-69.

Abstract

Background: The prognosis of acute lung injury (ALI) after pneumonectomy is poor, with reported mortality rates of 30-100%. Neutrophil elastase inhibitor (NEI) is known to prevent lung injury caused by neutrophil elastase and improve lung function in ALI. We evaluated the effect of NEI on ALI after pneumonectomy.

Methods: We analyzed nine patients who required ventilator care due to ALI after pneumonectomy. Five of these patients underwent conventional ventilator care (group I), and four patients underwent ventilator care and were administrated NEI (group II). We retrospectively analyzed the lung injury score (LIS) for 10 days after intubation.

Results: The LIS before intubation satisfied the diagnostic criteria of ALI or acute respiratory distress syndrome (ARDS) in all patients. After intubation, the LIS improved in both groups. But, as times went on, the mean value of the LIS in group II was lower compared to group I. In group I, only one patient underwent extubation. In group II, extubation was possible in three patients. Mortality rates were 80% in group I and 25% in group II.

Conclusions: We conclude that NEI may improve the lung function, shorten the duration of mechanical ventilation, and reduce mortality in patients with ALI after pneumonectomy.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / etiology
  • Acute Lung Injury / mortality
  • Acute Lung Injury / therapy
  • Adult
  • Aged
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Glycine / analogs & derivatives*
  • Glycine / therapeutic use
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Pneumonectomy*
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / mortality
  • Postoperative Complications / therapy
  • Proteinase Inhibitory Proteins, Secretory / therapeutic use*
  • Respiration, Artificial
  • Respiratory Distress Syndrome / drug therapy
  • Respiratory Distress Syndrome / etiology
  • Respiratory Distress Syndrome / mortality
  • Respiratory Distress Syndrome / therapy
  • Retrospective Studies
  • Sulfonamides / therapeutic use*
  • Treatment Outcome

Substances

  • Proteinase Inhibitory Proteins, Secretory
  • Sulfonamides
  • sivelestat
  • Glycine